Canary Capital’s Post

Canary Capital is pleased to share an updated research report on Biome Australia Group (ASX:BIO). We've added 2029 to our forecasts and lowered the company-specific risk premium by 0.5% to 2.5%, reflecting the company's strong performance and positive cash flow over the last three quarters. As a result our discounted cash flow valuation has increased to $1.10 per share, up from $0.79. The updated report also includes details on the new Biome Cholesterol product, updates on competitive barriers, and examples of recent pharmacy sales growth in mainland Australia. Please follow the link below to the Canary Capital website to read our updated research report: https://lnkd.in/dsQfACq4 #rerating #strongbuy #smallcap #asx #hypergrowth #probiotics

  • text, whiteboard
Stuart Craigie

Associate Director at Canary Capital Pty Ltd

4mo

Great update. Comprehensive update which clearly gives any reader an in-depth understanding of the company. Also really looking forward to lowering my Cholesterol!

Like
Reply

To view or add a comment, sign in

Explore topics